Becton, Dickinson and Company to Issue Quarterly Dividend of $1.05 (NYSE:BDX)

Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend on Tuesday, July 28th. Stockholders of record on Wednesday, September 9th will be paid a dividend of 1.05 per share by the medical instruments supplier on Wednesday, September 30th. This represents a c) annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Wednesday, September 9th.

Becton, Dickinson and Company has raised its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 53 consecutive years. Becton, Dickinson and Company has a payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Becton, Dickinson and Company to earn $13.48 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 31.2%.

Becton, Dickinson and Company Stock Up 0.8%

Becton, Dickinson and Company stock traded up $1.30 during mid-day trading on Wednesday, reaching $167.64. The stock had a trading volume of 201,136 shares, compared to its average volume of 2,726,077. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The company has a 50-day moving average price of $150.67 and a two-hundred day moving average price of $164.15. The company has a market capitalization of $46.19 billion, a price-to-earnings ratio of 42.54, a PEG ratio of 11.24 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the prior year, the firm posted $3.35 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BDX. TD Cowen lowered their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday, May 4th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research report on Monday, July 6th. Bank of America lowered their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Finally, The Goldman Sachs Group decreased their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $180.93.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.